Funding comes through the Covid-19 Therapeutics Accelerator, which was set up by Wellcome, Bill & Melinda Gates Foundation and Mastercard TOKYO and CAMBRIDGE, United Kingdom, Dec. 7, 2021
TOKYO and CAMBRIDGE, England, Aug. 12, 2021 /PRNewswire/ Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results
Share this article
Share this article
TOKYO and CAMBRIDGE, England, May 19, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new drug candidate nominated from the multi-target drug discovery collaboration between the two companies. Achievement of this milestone triggers a payment of US$5 million to Sosei Heptares. This candidate was nominated for advancement by Pfizer in December 2019 generating a US$3 million milestone payment at that time.
Pfizer nominated three distinct clinical candidates from the collaboration with Sosei Heptares during 2019, all of which are now progressing in Phase I clinical trials. These candidates have also now been disclosed by Pfizer as: